ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) –
BioTime, Inc.


/quotes/zigman/219441/quotes/nls/btx BTX
-0.29%



announced today that William Tew, Ph.D.,
BioTime’s Chief Commercial Officer will provide an update on the
development of Renevia(TM) (formerly known as HyStem(R)-Rx)
at an investor meeting in New York City. In his presentation, Dr. Tew
will discuss the global distribution network marketing the HyStem(R)
line of research products being utilized in a wide array of medical
research applications. Dr. Tew will also describe preclinical work
underway at medical institutions throughout the United States including
Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA,
Harvard Medical School, and the University of Florida. Finally, Dr. Tew
will discuss the product development milestones for the launch of Renevia(TM)
in Europe, with the goal of obtaining the CE mark necessary for
marketing Renevia(TM) in European Union countries by year-end
2013. Dr. Tew’s presentation and a video showing the potential use of
the product in reconstructive surgery will be available for viewing on
BioTime’s web site
www.biotimeinc.com .

Background

BioTime is a leader in developing, manufacturing, and marketing
proprietary biocompatible hydrogels that mimic the human extracellular
matrix (ECM). The human ECM is a web of molecules surrounding cells that
is essential to the formation, function, and growth of discrete tissues
and organs in the body. BioTime’s HyStem(R) hydrogels
are dynamic products that have the demonstrated ability to support the

Article source: http://www.marketwatch.com/story/biotime-provides-update-on-reneviatm-product-development-2012-04-23